Investigational Agent for Reduced Ejection Fraction Heart Failure

A pivotal Phase III trial studying a novel oral agent for heart failure with reduced ejection fraction (HFrEF) in patients already on optimized medical therapy.

Duration

18 months

Visits

15 visits

Compensation

Up to $900

Study Overview

This multicenter, randomized, double-blind, placebo-controlled Phase III trial evaluates the effect of an investigational oral agent on cardiovascular outcomes in patients with HFrEF (LVEF ≤40%). Participants will be randomized 1:1 to active treatment or placebo, added to standard-of-care therapy. Primary endpoint is a composite of cardiovascular death and worsening heart failure events at 18 months.

Eligibility Criteria

You May Qualify If:

Adults aged 18–80 with diagnosed HFrEF
LVEF ≤40% confirmed by echocardiogram
On stable, optimized medical therapy for ≥3 months
NYHA Class II–III symptoms

You May Not Qualify If:

Recent hospitalization for acute decompensated heart failure within 30 days
eGFR <20 mL/min/1.73m²
Systolic blood pressure <80 mmHg
Current participation in another interventional trial

Study Locations

Tampa Main Office

Apply for This Study

Complete this brief form and our team will contact you within 1 business day.

Questions? Call us directly:

(813) 815-7327

Back to All Studies